NEURALINK 2025: - Received FDA Breakthrough Device Designation for its speech restoration technology targeting severe speech impairments. - Launched its first clinical trial in the Middle East (UAE-PRIME) at Cleveland Clinic Abu Dhabi in partnership with the Department of